AstraZeneca Update on Anifrolumab in SLE
This announcement contains inside information31 August 2018 07:00 BST Update on TULIP 1 Phase III trial foranifrolumab in systemic lupus erythematosusTrial did not meet the primary endpoint of a reduction of disease activity as measured by the SLE Responder Index AstraZeneca and MedImmune, its global biologics research and development arm, todayannounced top-line results from the TULIP 1 Phase III trial for anifrolumab in adult patients with moderate-to-severe systemic lupus erythematosus (SLE). The trial did not meet the primary endpoint of a statistically-significant